Press Room

Emisphere in the News

News
	Emisphere Technologies, Inc. - Business and Financial Highlights Bio CEO Presentation Oct 25, 2011	233 KB
	Presentation at Bio CEO given by Interim CEO, Chief Financial Officer and Corporate Secretary, Michael R. Garone on Oct 25, 2011. Read more
	Reformulating Injectables for Delivery Pharmaceutical Technology Oct 2, 2011	762 KB
	Could oral absorption-enhancing technologies change the shape of protein delivery? Read more
	Brain Takes Multiple Hits from Low B12 Levels MedPage Today, www.medpagetoday.com Sept 26, 2011	23 KB
	Low levels of vitamin B12 may contribute to cognitive problems for older adults in more than one way, according to a cross-sectional study. Read more
	Oral Calcitonin Demonstrated Symptom-modifying Efficacy and Increased Cartilage Volume: Results from a 2-year Phase 3 Trial in Patients with Osteoarthritis of the Knee OARSI Abstract 64 Sept 15-18, 2011, San Diego, CA	104 KB
	Purpose: To evaluate the symptom- and structure-modifying efficacy and safety of oral salmon calcitonin (oCT) formulated with a 5-CNAC carrier (a molecule based on Eligen® technology from Emisphere), in patients with moderate to severe knee pain and structural damages classified as Kellgren-Lawrence 2-3 due to osteoarthritis (OA). Read more
	Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B12 Formulation and Intermittent Intramuscular Vitamin B12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-Group Study Clinical Therapeutics Volume 33, Number 3 - March 2011	867 KB
	Vitamin B12 deficiency is routinely treated with parental dosing and less often with high-dose vitamin B12. Oral vitamin B12 formulations have low bioavailability in patients with malabsorption and are considered less reliable than parenteral treatments. Read more
	Pharmacokinetics of Oral Cyanocobalamin Formulated With Sodium N-[8-(2-hydroxybenzoyl)amin]caprylate (SNAC): An Open-Label, Randomized, Single-Dose,Parallel-Group Study in Healthy Male Subjects Clinical Therapeutics Volume 33, Number 7 - July 2011	684 KB
	Vitamin B12 (cobalamin) deficiency may be caused by inadequate dietary intake of B12 or by conditions that result in malabsorption of the vitamin... Read more
	Improving Oral Drug Delivery Manufacturing Chemist March 2011	520. KB
	Poor permeability of pharmaceutical actives prevents many drugs from reaching the market. David Gschneidner, Emisphere Technologies, highlights a technology that can improve the delivery of water-soluble compounds Read more
	Emisphere Technologies - This biopharmaceutical company had to take a step back to move forward. Michael Novinksi explains. American Executive - May 2010	180. KB
	Some CEOs like to operate from a 30,000-foot perspective. Others prefer a more hands-on approach,... Read more
	Peri- and Postnatal Developmental Toxicity of Salcaprozate Sodium (SNAC) in Sprague-Dawley Rats International Journal of Toxicology Volume 28 Number 4 - July/August 2009	160 KB
	Salcaprozate sodium (SNAC) (sodium 8-((2-hydroxybenzoyl)amino) octanoate, CAS RN 203787-91-1) is classified as an oral absorption promoter... Read more
	Subchronic Oral Toxicity of Salcaprozate Sodium (SNAC) in Sprague-Dawley and Wistar Rats International Journal of Toxicology Volume 28 Number 4 - July/August 2009	180. KB
	Salcaprozate sodium (SNAC) (sodium 8-((2-hydroxybenzoyl)amino) octanoate, CAS RN 203787-91-1) is classified as an oral absorption promoter... Read more
	Drug Delivery Technology - Proteins & Peptides: Dependent on Advances in Drug Delivery Mar 2009	688 KB
	The success of protein and peptide therapeutics is revolutionizing the biotech and pharmaceutical market... Read more
	The New York Times - A Push for Adding B12, Though the Jury Is Out Oct 13, 2008	32. KB
	It has long been known that vitamins must be obtained from sources outside the body —food and drink, and for vitamin D, exposure to sunlight... Read more
	Inside Wall Street - A Biotech's Overseas Pacts Aug 4, 2008	136 KB
	Roche Holding’s (RHHBY) bid to buy all of Genentech (DNA) has reignited investor interest in U.S. biotechs... Read more
	Bloomberg.com - Novo to Pay Up to $87 Million to Emisphere for Drug Technology June 23, 2008	52 KB
	Novo Nordisk A/S, the world's biggest insulin producer, will pay as much as $87 million to U.S. drug formulator Emisphere Technologies Inc... Read more
	Drug Delivery Technology - The "New" Emisphere: Impacting the Future of Drug Delivery May 2008	956 KB
	Emisphere Technologies, Inc., (NASDAQ: EMIS), with corporate headquarters in Cedar Knolls, NJ, and its Scientific Center in Tarrytown, NY, is... Read more
	PharmaVOICE - The Last Word May 2008	188 KB
	Emisphere’s President and CEO Michael Novinski Considers the Changes in Drug Delivery... Read more
	Journal News - Emisphere Technologies Seeks Pill for Success May 4, 2008	396 KB
	On a recent warm spring morning, employees of Emisphere Technologies Inc. are gathered in a hallway at the biotechnology company's laboratories in the... Read more
	The Wall Street Transcript - Company Interview - Michael V. Novinski Apr 28, 2008	212 KB
	Emisphere Technologies, Inc., which has been in business for nearly 20 years, is a biopharmaceutical company that focuses on developing oral forms of injectable drugs... Read more
	The Daily Record - CEO energized about new drug technology Apr 8, 2008	324 KB
	Michael V. Novinski, a veteran in the pharmaceutical industry, has been president and CEO at Emisphere Technologies in Cedar Knolls since May 2007... Read more
	The Star Ledger - Untapped Potential Mar 20, 2008	392 KB
	For two decades Emisphere Technologies has struggled to get it's footing... Read more
	BioWorld Today - Emisphere Relaunches After Turbulent Past Feb 12, 2008	64.0 KB
	Emisphere Technologies Inc. last year underwent a major restructuring, which included cutting employees, moving its corporate headquarters from Tarrytown, N.Y., to Cedar Knolls, N.J., and hiring Michael Novinski to lead the firm... Read more

Careers | Sitemap | Contact